CA
NZ
UK
AU
IND
US
Travere Therapeutics (NASDAQ: TVTX) shares closed up 12% at $62.76 after Citi raised its price target to $85 from $70 while maintaining a Buy rating, citing better-than-expected Q2 results.
Citius Pharmaceuticals (NASDAQ: CTXR) shares closed up 25% at $0.78 after majority-owned Citius Oncology reported accelerating LYMPHIR uptake in cutaneous T-cell lymphoma (CTCL).
Geron (NASDAQ: GERN) shares closed up 22% at $1.63 after the company reported Q2 FY2026 revenue exceeding forecasts, bolstered by Rytelo net product sales of $57.5 million, an 11% sequential increase.
Sight Sciences (NASDAQ:SGHT) announced that Aetna's updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI Surgical System and the SION Surgical Instrument as medically necessary for the treatment of mild-to-moderate open-angle glaucoma when specified clinical criteria are met. Co-Founder and Chief …
Vir Biotechnology is trading higher in pre-market action after delivering a second-quarter report that beat expectations on both revenue and earnings, alongside encouraging new clinical data. Shares rose as much as 6.59% to $9.71 in pre-market trading, adding to a 3.03% gain from two …
Galectin Therapeutics is trading higher in pre-market action after announcing a major balance sheet transformation. Shares rose as much as 4.85% to $3.24 in pre-market trading, following a 3.34% gain in the prior regular session, as investors welcomed news that the company's largest stockholder …
Geron is trading modestly lower in pre-market action today, pulling back after a sharp rally in the prior session following the company's second-quarter earnings report. Shares fell as much as 5.52% to $1.54 in pre-market trading, after closing up 21.64% at $1.63 on Wednesday.
Ginkgo Bioworks is trading lower today after the synthetic biology company reported second-quarter revenue that fell short of Wall Street expectations. Shares declined as much as 4.06% to $8.99 in pre-market trading, a continuation of Wednesday's session in which the stock closed flat.
Moderna (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration has approved mFLUSIVA, a new vaccine against seasonal influenza, for use in all adults 50 years of age and older. The approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory …
Moderna is trading higher in pre-market action after the U.S. Food and Drug Administration approved mFLUSIVA, a new seasonal influenza vaccine built on the company's mRNA platform. Shares rose as much as 3.35% to $58.14 in pre-market trading, following a roughly flat prior regular …
Please wait processing your request...